Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer

Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans. See related Spotlight, p. 787.

Saved in:
Bibliographic Details
Published in:Cancer prevention research (Philadelphia, Pa.) Pa.), 2022-12, Vol.15 (12), p.791-802
Main Authors: Mazumdar, Abhijit, Tahaney, William M, Hill, Jamal L, Zhang, Yun, Ramachandran, Sumankalai, Kawedia, Jitesh, Qian, Jing, Contreras, Alejandro, Savage, Michelle I, Vornik, Lana A, Sei, Shizuko, Mohammed, Altaf, Brown, Powel H
Format: Article
Language:English
Subjects:
Animals
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - prevention & control
Everolimus - pharmacology
Everolimus - therapeutic use
Female
Humans
Mammary Neoplasms, Animal
Mice
Receptors, Estrogen - metabolism
TOR Serine-Threonine Kinases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans. See related Spotlight, p. 787.
ISSN:1940-6207
1940-6215
DOI:10.1158/1940-6207.CAPR-22-0106